Wed, Apr 16, 2014, 6:21 AM EDT - U.S. Markets open in 3 hrs 9 mins

Recent

% | $
Quotes you view appear here for quick access.

SIGA Technologies, Inc. Message Board

homebuilder_watcher 2530 posts  |  Last Activity: 15 hours ago Member since: Dec 4, 2001
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Grafix will win the race

    by ozark580 Apr 13, 2014 1:46 PM
    homebuilder_watcher homebuilder_watcher 15 hours ago Flag

    But, you all can just watch and learn. Watch what happens to EpiFix sales for the balance of the year vs Grafix (any insurance coverage from MACs yet cause you know, you cant sell it if it isn't covered. Oh, I didn't think you had any of the 9 yet unlike EpiFix which has 9 of 9). By the end of the year Epifix will be firmly entrenched. of course, Epifix is not even where MDXG's future lies in any event.

  • Reply to

    Grafix will win the race

    by ozark580 Apr 13, 2014 1:46 PM
    homebuilder_watcher homebuilder_watcher 15 hours ago Flag

    Our reimbursement successes are attributed to the data we have collected in our peer-reviewed published clinical trials," stated Petit. "We have four different publications in Level One Journals on EpiFix®, our wound care allograft. We also have several other supporting scientific and clinical publications. Shortly, we will announce the publication of a 90-patient study on venous leg ulcers ("VLUs"). This is a multi-center, randomized, controlled trial involving seven centers. This should clear any questions on the effectiveness of EpiFix® on the larger VLU wounds. Shortly after this publication, we expect to announce another publication of a study of 60 patients with diabetic foot ulcers. This will bring our total study population to well over 200 patients.

    And from the last conf call

    And I will remind you of something I have also said before, our best sales through was simply the usage of EpiFix by just not any wound care physician. Scientists or researchers can argue all day long about which clinical study is better than some other study, but what’s non-debatable as a result of the use of a product in the hands of the typical wound care doctor in a widely diverse patient population. Our best sales through is to have a physician use an evaluation sample of EpiFix on a patient of theirs who had a chronic wound that he or she has not been able to close for months. And then we will come back to that position one or two weeks after that initial application, response when we see the doctor again is almost always the same.

    What’s in that graft? The wound that is installed for months has either healed or significantly reduced the size. So personally, I don’t care if it’s better as a clinical study of 20, 50 or 500 people, none of them have shown the clinical performance of EpiFix noted most of them have the very simple logistics to the use of MiMedx. They can’t compete clinically or cost effectively so they try to focus and divert attention to something else.

  • Reply to

    Grafix will win the race

    by ozark580 Apr 13, 2014 1:46 PM
    homebuilder_watcher homebuilder_watcher 19 hours ago Flag

    Ozark, as an attorney allow me to explain to you how the doctor will respond to that question. "Because sir, the fact that one product has live cells and one has dead cells isn't relevant to my decision which product to use. My decision was based on clinical studies that showed EpiFix is more effective than Grafix. What is in the product doesn't concern me, only the results."

  • homebuilder_watcher by homebuilder_watcher Apr 14, 2014 12:57 PM Flag

    News on the very surprising injunction granted on one of their products..on Yahoo if you look. Just read a note that it is a blow to their pipeline. I know just the "fix" for them..Amniofix and Epifix

  • Reply to

    Here comes $4.00

    by halloweencandy2013 Apr 12, 2014 9:26 AM
    homebuilder_watcher homebuilder_watcher Apr 12, 2014 10:31 AM Flag

    Saw this today and applies perfectly in this case. "never argue with an idiot. They will only bring you down to their level and beat you with experience."

  • Reply to

    Biotech

    by mbwright1970 Apr 11, 2014 9:53 AM
    homebuilder_watcher homebuilder_watcher Apr 11, 2014 11:26 AM Flag

    No, that is retail conspiracy fodder

  • Reply to

    Biotech

    by mbwright1970 Apr 11, 2014 9:53 AM
    homebuilder_watcher homebuilder_watcher Apr 11, 2014 10:21 AM Flag

    It all started with pharmas being pressured in DC about lowering drug prices, then the general rotation out of stocks perceives as having lofty valuations. Stocks with ultra high PEs with the biggest runnups hardest hits. Bios and pharmas with no revenue easy targets for sell offs as they trade on future prospects since many have no revenue yet

  • homebuilder_watcher by homebuilder_watcher Apr 11, 2014 10:18 AM Flag

    TRX 164 vs 136 prior. NRx 140 vs 118 prior

  • Reply to

    market_mania, Bubble, Ozark

    by homebuilder_watcher Apr 10, 2014 11:17 AM
    homebuilder_watcher homebuilder_watcher Apr 10, 2014 11:38 AM Flag

    Be afraid. be very afraid. Just like when you try to panic MDXG shareholders when it is down on light volume.

  • homebuilder_watcher by homebuilder_watcher Apr 10, 2014 11:17 AM Flag

    The CFO made a trip to the bank this week to deposit $15 million. Stock is tanking today. I don't understand. How can that be with all that cash and more on the way? I mean Apple has like $50 billion in cash and awarded a PE of 12. Wait, you think the market is concerned about how OSIR is going to compete with EpiFix when EpiFix is approved for reimbursement from 9 of the 9 MACs and Grafix is approved by zero of the 9 Macs? Silly me.

  • Reply to

    Predictable

    by earth457 Apr 8, 2014 10:26 AM
    homebuilder_watcher homebuilder_watcher Apr 10, 2014 11:00 AM Flag

    Hard to predict but I suspect we could see some bombs dropped this year

  • homebuilder_watcher homebuilder_watcher Apr 9, 2014 10:10 PM Flag

    Your fund? Funny. Your piggy bank fund

  • homebuilder_watcher by homebuilder_watcher Apr 9, 2014 5:27 PM Flag

    Looks like I was off in an earlier post today. It's up to 36.4% now. Largest holders with their % in ( ) after the name who hold at least 1 million shares are: ADEC (4.74%), Jackson Investment Group (4.29%), Blackrock (3.4%), Cox Road partners (2.37%), MFS (2.28%), Vanguard (2.05%), B of A (1.33%), Northern Trust (1.25%), State Street (1.25%), Fidelity (1.18%), Tamarack Capital (1.14%), JP Morgan (1.1%), Wellington (0.06%)

  • Reply to

    Osiris to the bank

    by bub.bles22 Apr 9, 2014 11:03 AM
    homebuilder_watcher homebuilder_watcher Apr 9, 2014 4:18 PM Flag

    OSIR might sell Grafix for zero to someone like the other wana be did last year

  • Reply to

    How many corporate officers leave today?

    by investor.madmax Apr 8, 2014 8:35 AM
    homebuilder_watcher homebuilder_watcher Apr 9, 2014 2:39 PM Flag

    where did the "buying power go" the last 6-8 weeks? Same place it went for the rest of stocks, particularly Nasdaq and particularly anything perceived as bio, into cash and out of stocks.

  • Reply to

    growth

    by how_bout_we_talk Apr 9, 2014 12:07 PM
    homebuilder_watcher homebuilder_watcher Apr 9, 2014 12:24 PM Flag

    I might be wrong but I do not think they have the injectable included in their guidance for the year. I expect revs for 2014 closer to 120M

  • Reply to

    Predictable

    by earth457 Apr 8, 2014 10:26 AM
    homebuilder_watcher homebuilder_watcher Apr 9, 2014 12:21 PM Flag

    how_bout_we_talk, take a look at ICPT and its market cap, with no approved product merely a speculative value based on uncompleted trials

  • Reply to

    Osiris to the bank

    by bub.bles22 Apr 9, 2014 11:03 AM
    homebuilder_watcher homebuilder_watcher Apr 9, 2014 12:19 PM Flag

    Correct.OSIR's PRODUCT revenues in Q4 were $8 million, MDXG were $18 million. I believe the divide between the two will expand throughout 2014. It's tough to sell your product when you have not one MAC in the country that has approved Grafix for reimbursement as opposed to MDXG having every one of them approved. Bubble brain and his other Sybils don't quite grasp that concept. But, they will learn, the hard way.

  • Reply to

    How many corporate officers leave today?

    by investor.madmax Apr 8, 2014 8:35 AM
    homebuilder_watcher homebuilder_watcher Apr 9, 2014 9:37 AM Flag

    ozark, you are simply a morn and what's worse, a moron that can't even read and grasp simple financial terms. Do you understand what 5 times over subscribed means? it doesn't mean that a company issued more stock than it offered, it means that for every share they offered in their secondary, there was a demand for 5 times more nitwit. It means if they were selling 5 million shares as an example, they were contacted by institutions who if you added up their request, their was demand for 25 million shares. They still sold only 5 million nitwit. And, like most retail investors, you do not understand what the term "dilution means". Issuing stock is not necessarily dilutive at all the shareholders. Ever see a PR from a company acquiring another company in a stock deal where it says "the acquisition will be immediately accretive to earnings'. Is that dilution to shareholders? No, it is dilutive to S/h when stock is issued and EPS declines as a result,. When the cash raised is used to grow the business and EPS rises as a result, it was not dilutive.

  • homebuilder_watcher homebuilder_watcher Apr 9, 2014 8:32 AM Flag

    We should. Up to 29% inst ownership as of 12/31, a lot more than previously including a lot of new ones including MFS

SIGA
2.79-0.10(-3.46%)Apr 15 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Yahoo! Inc.
NasdaqGSTue, Apr 15, 2014 4:00 PM EDT
Zebra Technologies Corp.
NasdaqGSTue, Apr 15, 2014 4:00 PM EDT